SCIELE PHARMA, INC. (SLRX) is a publicly traded company in the Unknown sector. Across all available filings, 11 corporate insiders have executed 60 transactions totaling $259.8K, demonstrating a bullish sentiment with $259.8K in net insider flow. The most recent transaction on Nov 20, 2025 involved a purchase of 20,000 shares valued at $16.0K.
No significant insider buying has been recorded for SLRX in the recent period.
No significant insider selling has been recorded for SLRX in the recent period.
Based on recent SEC filings, insider sentiment for SLRX is bullish with an Insider Alignment Score of 100/100 and a net flow of $259.8K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at SCIELE PHARMA, INC. (SLRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 11 insiders are actively trading SLRX stock, having executed 60 transactions in the past 90 days. The most active insider is Jon S. Saxe (Executive), who has made 1 transactions totaling $253.3K.
Get notified when executives and directors at SLRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | J. Rosenblum Mark | Executive | Purchase | 20,000 | $0.80 | $16.0K | |
| Nov 20, 2025 | C. Hanish Arnold | Executive | Purchase | 5,000 | $0.75 | $3.8K | |
| Feb 13, 2023 | J. Arthur David | Executive | Award | 14,300 | $N/A | $0 | |
| Feb 13, 2023 | J. Rosenblum Mark | Executive | Award | 6,432 | $N/A | $0 | |
| Jan 3, 2023 | J. Arthur David | Executive | Award | 20,000 | $N/A | $0 | |
| Jan 3, 2023 | J. Rosenblum Mark | Executive | Award | 8,000 | $N/A | $0 | |
| Jan 3, 2023 | K. Mcvicar William | Executive | Award | 1,440 | $N/A | $0 | |
| Jan 3, 2023 | Burleson Tess | Executive | Award | 1,440 | $N/A | $0 | |
| Jan 3, 2023 | Lammers Paul | Executive | Award | 1,440 | $N/A | $0 | |
| Jan 3, 2023 | C. Hanish Arnold | Executive | Award | 1,440 | $N/A | $0 | |
| Jan 3, 2023 | J. Mccreedy Bruce Jr | Executive | Award | 1,440 | $N/A | $0 | |
| Jan 3, 2023 | I. Lieber Jonathan | Executive | Award | 1,440 | $N/A | $0 | |
| Nov 3, 2022 | J. Rosenblum Mark | Executive | Award | 7,314 | $1.73 | $12.7K | |
| Nov 3, 2022 | J. Arthur David | Executive | Award | 10,000 | $1.73 | $17.3K | |
| Nov 3, 2022 | J. Rosenblum Mark | Executive | Award | 7,314 | $1.73 | $12.7K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Award(A) | 25 | $352.0K | 57.5% |
Purchase(P) | 35 | $259.8K | 42.5% |
Insiders at SCIELE PHARMA, INC. are accumulating shares at an accelerated pace. With 11 insiders making 60 transactions totaling $259.8K in purchases versus $0 in sales, the net buying activity of $259.8K signals strong executive confidence. Jon S. Saxe (Executive) leads the buying activity with $253.3K in transactions across all time.